Clinicopathological and prognostic significance of Yes-associated protein expression in hepatocellular carcinoma and hepatic cholangiocarcinoma

Tumor Biology

Volumn 37, Issue 10, 2016, Pages 13499-13508

  Wu, Hao ^a   Liu, Yan ^b   Jiang, Xiao Wei ^c   Li, Wen Fang ^d   Guo, Gang ^e   Gong, Jian Ping ^a   Ding, Xiong ^a  

^a THE SECOND AFFILIATED HOSPITAL OF CHONGQING MEDICAL UNIVERSITY   (China)

^b CHENGDU FIFTH PEOPLE S HOSPITAL   (China)

^c The Fifth People's Hospital of Chongqing   (China)

^d WUHAN UNIVERSITY   (China)

^e SICHUAN UNIVERSITY   (China)

Author keywords

Hepatic cholangiocarcinoma; Hepatocellular carcinoma; Immunohistochemistry; Yes associated protein(YAP)

Indexed keywords

PROTEIN; UNCLASSIFIED DRUG; YES ASSOCIATED PROTEIN; PHOSPHOPROTEIN; SIGNAL TRANSDUCING ADAPTOR PROTEIN; TUMOR MARKER; YAP1 (YES-ASSOCIATED) PROTEIN, HUMAN;

ADULT; ARTICLE; BILE DUCT CARCINOMA; CANCER PROGNOSIS; CANCER SURGERY; CARCINOGENESIS; DISEASE ASSOCIATION; DISEASE SPECIFIC SURVIVAL; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PROTEIN EXPRESSION; RECURRENCE FREE SURVIVAL; SURVIVAL RATE; TUMOR GROWTH; TUMOR INVASION; TUMOR VOLUME; BILE DUCT NEOPLASMS; CANCER STAGING; CARCINOMA, HEPATOCELLULAR; CHOLANGIOCARCINOMA; ENZYME IMMUNOASSAY; FOLLOW UP; INTRAHEPATIC BILE DUCT; LIVER NEOPLASMS; LYMPH NODE METASTASIS; METABOLISM; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PROGNOSIS; SECONDARY; SIGNAL TRANSDUCTION; TUMOR RECURRENCE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; BIOMARKERS, TUMOR; CARCINOMA, HEPATOCELLULAR; CHOLANGIOCARCINOMA; COMBINED MODALITY THERAPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; LIVER NEOPLASMS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PHOSPHOPROTEINS; PROGNOSIS; SIGNAL TRANSDUCTION; SURVIVAL RATE;

EID: 84980018556     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-016-5211-y     Document Type: Article

References (30)

1. Media centre. Title of subordinate document. In: Cancer. 2015. http://www.who.int/mediacentre/factsheets/fs297/en/. Accessed 18 Feb 2015.
2. Koh KC, Lee H, Choi MS, et al. Clinicopathologic features and prognosis of combined hepatocellular cholangiocarcinoma. Am J Surg. 2005;189:120–5.
3. Wang J, Wang F, Kessinger A. Outcome of combined hepatocellular and cholangiocarcinoma of the liver. Journal of Oncology Volume. 2010. doi:10.1155/2010/917356.
4. Bosetti C, Turati F, Vecchia CL. Hepatocellular carcinoma epidemiology. Best Pract Res Clin Gastroenterol. 2014;28:753–70.
5. Ertle JM, Heider D, Wichert M, Keller B, Kueper R, Hilgard P, et al. A combination of alpha-fetoprotein and des-gamma-carboxy prothrombin is superior in detection of hepatocellular carcinoma. Digestion. 2013;87:121–31.
6. Wang XM, Yang LY, Guo L, Fan C, Wu F. p53-induced RING-H2 protein, a novel marker for poor survival in hepatocellular carcinoma after hepatic resection. Cancer. 2009;115:4554–63.
7. Johnson R, Halder G. The two faces of Hippo: targeting the Hippo pathway for regenerative medicine and cancer treatment. Nat Rev Drug Discov. 2013;13:63–79.
8. Harvey KF, Zhang X, Thomas DM. The Hippo pathway and human cancer. Nat Rev Cancer. 2013;13:246–57.
9. Huang J, Wu S, Barrera J, et al. The Hippo signaling pathway coordinately regulates cell proliferation and apoptosis by inactivating Yorkie, the Drosophila homolog of YAP. Cell. 2005;122(3):421–34.
10. Edgar BA. From cell structure to transcription: Hippo forges a new path. Cell. 2006;124(2):267–73.
11. Kim JE, Finlay GJ, Baguley BC. The role of the hippo pathway in melanocytes and melanoma. Front Oncol. 2013;3:123.
12. Komuro A, Nagai M, Navin NE, et al. WW domain-containing protein YAP associates with ErbB-4 and acts as a co-transcriptional activator for the carboxyl-terminal fragment of ErbB-4 that translocates to the nucleus. J Biol Chem. 2003;278(35):33334–41.
13. Nallet-Staub F, Marsaud V, Li L, et al. Pro-invasive activity of the Hippo pathway effectors YAP and TAZ in cutaneous melanoma. J Invest Dermatol. 2014;134:123–32.
14. Morvaridi S, Dhall D, Greene M, et al. Role of YAP and TAZ in pancreatic ductal adenocarcinoma and in stellate cells associated with cancer and chronic pancreatitis. Scientific Reports. 2015;5:16759.
15. Zender L, Spector MS, Xue W, et al. Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach. Cell. 2006;125:1253–67.
16. He C, Mao D, Hua G, et al. The Hippo/YAP pathway interacts with EGFR signaling and HPV oncoproteins to regulate cervical cancer progression. EMBO Molecular Medicine. 2015;7(11):1426–49.
17. Maugeri-Saccà M, Barba M, Pizzuti L, et al. The Hippo transducers TAZ and YAP in breast cancer: oncogenic activities and clinical implications. Expert Rev Mol Med. 2015. doi:10.1017/erm.2015.12.
18. Wang Y, Dong Q, Zhang Q, Li Z, Wang E, Qiu X. Overexpression of yesassociated protein contributes to progression and poor prognosis of nonsmall-cell lung cancer. Cancer Sci. 2010;101:1279–85.
19. Kang W, Tong JH, Chan AW. Yes-associated protein 1 exhibits oncogenic property in gastric cancer and its nuclear accumulation associates with poor prognosis. Clin Cancer Res. 2011;17:2130–9.
20. Avruch J, Zhou D, Bardeesy N. YAP oncogene overexpression supercharges colon cancer proliferation. Cell Cycle. 2012;11:1090–6.
21. Kim M, Kim T, Johnson RL, et al. Transcriptional Co-repressor function of the Hippo pathway transducers YAP and TAZ. Cell Rep. 2015;11(2):270–82.
22. Wang Y, Xie C, Li Q, et al. Clinical and prognostic significance of Yes-associated protein in colorectal cancer. Tumor Biol. 2013;34:2169–74.
23. Zhao B, Wei X, Li W, et al. Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. Genes Dev. 2007;21:2747–61.
24. Xu MZ, Yao TJ, Lee NP, et al. Yes-associated protein is an independent prognostic marker in hepatocellular carcinoma. Cancer. 2009;115:4576–85.
25. Li H, Wang S, Wang G, et al. Yes-associated protein expression is a predictive marker for recurrence of hepatocellular carcinoma after liver transplantation. Dig Surg. 2014;31(6):468–78.
26. Yang X, Xu T. Molecular mechanism of size control in development and human diseases. Cell Res. 2011;21:715–29.
27. Dong J, Feldmann G, Huang J, Comerford SA, et al. Elucidation of a universal size-control mechanism in drosophila and mammals. Cell. 2007;130(6):1120–33.
28. Zhao B, Ye X, Yu J, et al. TEAD mediates YAP-dependent gene induction and growth control. Genes Dev. 2008;22:1962–71.
29. Hen L, Loh PG, Song H. Structural and functional insights into the TEAD-YAP complex in the hippo signaling pathway. Protein Cell. 2010;1:1073–83.
30. Hao Y, Chun A, Cheung K, et al. Tumor suppressor LATS1 is a negative regulator of oncogene YAP. J Biol Chem. 2008;283:5496–509.